OBJECTIVE: The aim of this paper is to review the anti-inflammatory cytokines IL-4 and IL-13 and their receptor signals; we discuss new insight into their possible roles in systemic sclerosis (SSc) and their overlapping function in SSc. INTRODUCTION: SSc is a connective tissue disease characterized by fibrosis. The exact etiology of SSc is unknown, and no therapy has been proved effective in modifying its course. Recently the roles of IL-4 and IL-13 in the development of SSc have been extensively considered. The possible roles of IL-4 and IL-13, especially their overlapping function, in SSc are not well documented. METHODS: A literature survey was performed using a PubMed database search to gather complete information regarding IL-4 and IL-13 and their role in inflammation. RESULTS AND CONCLUSIONS: The participation of complex pathways of IL-4 and IL-13 in the process of inflammation and fibrosis action in SSc is still not very clear, and some pathogenesis of regulation found in vitro needs to be further proved. There is still more work which could be done to achieve useful developments with therapeutic benefit in SSc.
OBJECTIVE: The aim of this paper is to review the anti-inflammatory cytokines IL-4 and IL-13 and their receptor signals; we discuss new insight into their possible roles in systemic sclerosis (SSc) and their overlapping function in SSc. INTRODUCTION: SSc is a connective tissue disease characterized by fibrosis. The exact etiology of SSc is unknown, and no therapy has been proved effective in modifying its course. Recently the roles of IL-4 and IL-13 in the development of SSc have been extensively considered. The possible roles of IL-4 and IL-13, especially their overlapping function, in SSc are not well documented. METHODS: A literature survey was performed using a PubMed database search to gather complete information regarding IL-4 and IL-13 and their role in inflammation. RESULTS AND CONCLUSIONS: The participation of complex pathways of IL-4 and IL-13 in the process of inflammation and fibrosis action in SSc is still not very clear, and some pathogenesis of regulation found in vitro needs to be further proved. There is still more work which could be done to achieve useful developments with therapeutic benefit in SSc.
Authors: Etsushi Kuroda; Frann Antignano; Victor W Ho; Michael R Hughes; Jens Ruschmann; Vivian Lam; Toshiaki Kawakami; William G Kerr; Kelly M McNagny; Laura M Sly; Gerald Krystal Journal: J Immunol Date: 2010-12-03 Impact factor: 5.422
Authors: Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis Journal: Arthritis Rheum Date: 2011-06
Authors: Xin Yao; Wangjian Zha; Wei Song; Haiyan He; Mao Huang; Elen Jazrawi; Paul Lavender; Peter J Barnes; Ian M Adcock; Andrew L Durham Journal: Biochem Biophys Res Commun Date: 2011-12-27 Impact factor: 3.575
Authors: Hong-Erh Liang; R Lee Reinhardt; Jennifer K Bando; Brandon M Sullivan; I-Cheng Ho; Richard M Locksley Journal: Nat Immunol Date: 2011-12-04 Impact factor: 25.606
Authors: Armand O Brown; Kavindra V Singh; Melissa R Cruz; Karan Gautam Kaval; Liezl E Francisco; Barbara E Murray; Danielle A Garsin Journal: J Infect Dis Date: 2021-02-13 Impact factor: 5.226
Authors: Kevin M Motz; Linda X Yin; Idris Samad; Dacheng Ding; Michael K Murphy; Madhavi Duvvuri; Alexander T Hillel Journal: Otolaryngol Head Neck Surg Date: 2017-05-09 Impact factor: 3.497
Authors: Anastasiya Muntyanu; Michelle Le; Zainab Ridha; Elizabeth O'Brien; Ivan V Litvinov; Philippe Lefrançois; Elena Netchiporouk Journal: J Cell Commun Signal Date: 2021-08-03 Impact factor: 5.782